Jaena
Lv66
2290 积分
2022-03-22 加入
-
Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning
12天前
已完结
-
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
13天前
已完结
-
Recommendations for accurate reporting in medical research statistics
2个月前
已完结
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
-
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma
4个月前
已完结
-
Cancer Immunology and Immunotherapy Showcased in the AACR Cancer Progress Report 2023
6个月前
已完结
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
6个月前
已完结
-
Immunotherapies for hepatocellular carcinoma
7个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7个月前
已完结